SWOG
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1956-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.swog.org
Clinical Trials
328
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (283 trials with phase data)• Click on a phase to view related trials
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- Conditions
- Colorectal Cancer Stage IIColorectal Cancer Stage III
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1057
- Registration Number
- NCT07018869
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
- Conditions
- Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyOther: Questionnaire Administration
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 94
- Registration Number
- NCT06998940
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- Conditions
- Lung Small Cell Carcinoma, I SubtypeLung Small Cell Carcinoma, N SubtypeLung Small Cell Carcinoma, P SubtypeExtensive Stage Lung Small Cell CarcinomaLung Small Cell Carcinoma, A Subtype
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingDrug: Platinum CompoundProcedure: Positron Emission TomographyRadiation: Thoracic Radiation Therapy
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 900
- Registration Number
- NCT06769126
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
- Conditions
- Pancreatic CarcinomaPancreatic Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Distal PancreatectomyOther: Questionnaire AdministrationOther: Saline
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 274
- Registration Number
- NCT06807437
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
- Conditions
- CD19+ Acute LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 55
- Registration Number
- NCT06773936
- Prev
- 1
- 2
- 3
- 4
- 5
- 66
- Next
News
BostonGene Partners with SWOG Cancer Research Network for AI-Driven Small Cell Lung Cancer Precision Medicine Trial
BostonGene and SWOG Cancer Research Network launched the PRISM study, a randomized Phase II trial evaluating biomarker-directed therapy for extensive stage small cell lung cancer patients.
Urine DNA Test Predicts Bladder Cancer Recurrence After Immunotherapy Treatment
A multi-institutional study published in Science Direct demonstrates that urine-based tumor DNA (utDNA) testing can predict which bladder cancer patients face higher recurrence risk after immunotherapy treatment.
World Cancer Day Highlights Critical Need to Address Oncology Care Disparities
Financial hardship affects 50-70% of cancer patients in community settings, leading to treatment adherence issues and worse outcomes, particularly among underserved populations.
PROSPECT-Lung Trial Investigates Optimal Timing of Immunotherapy in Non-Small Cell Lung Cancer
The PROSPECT-Lung trial is evaluating whether immunotherapy is more effective when administered before or after surgery for resectable non-small cell lung cancer.
FDA Updates Fludarabine Phosphate Labeling for CLL Treatment
The FDA has updated the labeling for fludarabine phosphate, expanding its approved use in treating B-cell chronic lymphocytic leukemia (CLL).
Extended Lymph Node Removal Fails to Improve Survival in Muscle-Invasive Bladder Cancer
A recent clinical trial found that extended lymph node removal during bladder cancer surgery does not improve overall or disease-free survival compared to standard removal.
myeloMATCH Trials Open to Accelerate Precision Medicine for AML and MDS
myeloMATCH, a collaborative effort by leading cancer research organizations, launches clinical trials to advance precision medicine for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Extended Lymphadenectomy Fails to Improve Survival in Muscle-Invasive Bladder Cancer
A phase III trial (SWOG S1011) found that extended lymphadenectomy did not improve disease-free survival compared to standard lymphadenectomy in patients with muscle-invasive bladder cancer.
Strategic Collaborations and Novel Therapies Advance Cancer and Brain Injury Treatment
• AstraZeneca and Moffitt Cancer Center are collaborating to accelerate cell therapy development, focusing on CAR T and TCR T therapies for solid tumors. • SWOG Cancer Research Network developed a risk prediction model to identify cancer patients at high risk for emergency room visits during clinical trials. • A national clinical trial is launched by UC San Francisco to repurpose existing drugs for treating traumatic brain injury (TBI), addressing a critical unmet need. • The Ohio State University initiates clinical trials for HOSU-53, a novel DHODH inhibitor, in partnership with Jabez Biosciences, targeting cancer metabolism.
Risk Prediction Model Identifies Cancer Patients Prone to ER Visits During Clinical Trials
A new risk prediction model identifies advanced cancer patients in clinical trials at high risk for unplanned ER visits and hospital stays.